BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35126610)

  • 41. External quality assurance in nongynecologic cytology: The Australasian experience.
    Shield PW; Frost F; Finnimore JL; Wright RG; Cummings MC
    Cancer Cytopathol; 2017 May; 125(5):349-361. PubMed ID: 28241108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of the international system for reporting serous fluid cytopathology on reporting various body fluids; experience of a tertiary care hospital.
    Kolte S; Zaheer S; Aden D; Ranga S
    Cytojournal; 2022; 19():52. PubMed ID: 36128470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of liquid-based cytology and ancillary techniques in pleural and pericardic effusions: an institutional experience.
    Rossi ED; Bizzarro T; Schmitt F; Longatto-Filho A
    Cancer Cytopathol; 2015 Apr; 123(4):258-66. PubMed ID: 25641902
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids.
    Afify A; Pang L; Howell L
    Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):446-50. PubMed ID: 18091389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The value of cytology in diagnosis of serous effusions in malignant lymphomas: An experience of a tertiary care center.
    Patel T; Patel P; Mehta S; Shah M; Jetly D; Khanna N
    Diagn Cytopathol; 2019 Aug; 47(8):776-782. PubMed ID: 31091023
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic accuracy of International System for Reporting Serous Fluid Cytopathology: A systematic review and meta-analysis in malignancy diagnosis.
    Ahuja S; Ahuja R; Pandey S; Zaheer S
    Cancer Cytopathol; 2024 Apr; ():. PubMed ID: 38613789
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of the International System for Reporting Serous Fluid Cytopathology (ISRSFC) in reporting serous effusion: A retrospective study.
    Yang H; Zhu J; Wang P
    Medicine (Baltimore); 2023 Oct; 102(43):e35707. PubMed ID: 37904355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The international system for reporting serous fluid cytopathology: The initial project survey.
    VandenBussche CJ; Crothers B; Chandra A; Schmitt F; Kurtycz DFI
    Cytopathology; 2023 May; 34(3):191-197. PubMed ID: 36752688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The diagnosis of malignancy in effusion cytology: a pattern recognition approach.
    Pereira TC; Saad RS; Liu Y; Silverman JF
    Adv Anat Pathol; 2006 Jul; 13(4):174-84. PubMed ID: 16858151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating Diagnostic Clarity: The Comparative Efficacy of BlueStain in Serous Effusion Cytology under the International System for Reporting Serous Fluid Cytopathology Reporting Framework.
    Alves PM; Azevedo MT; Ferreira F; Tastekin E; Canberk S; Schmitt FC
    Diagnostics (Basel); 2024 May; 14(11):. PubMed ID: 38893601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lymphoreticular malignancies in serous effusions: Cytomorphologic, flow cytometric and immunocytochemical analysis.
    Gupta P; Pandey T; Gautam U; Rajwanshi A; Srinivasan R; Gupta N; Rohilla M; Varma N; Dey P
    Diagn Cytopathol; 2021 May; 49(5):647-656. PubMed ID: 33629825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of the International System for Reporting Serous Fluid Cytopathology (TIS): A retrospective institutional study.
    Straccia P; Chiappetta M; Magnini D; Cancellieri A
    Cytopathology; 2022 May; 33(3):305-311. PubMed ID: 35213747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Converting fluid-based cytologic specimens to histologic specimens for immunohistochemistry.
    Wallace KA; Goldschmidt MH; Patel RT
    Vet Clin Pathol; 2015 Jun; 44(2):303-9. PubMed ID: 25639814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparative analysis of conventional cytopreparatory and liquid based cytological techniques (Sure Path) in evaluation of serous effusion fluids.
    Dadhich H; Toi PC; Siddaraju N; Sevvanthi K
    Diagn Cytopathol; 2016 Nov; 44(11):874-879. PubMed ID: 27546351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The value of exfoliative cell cytology in the diagnosis of exudative pleural effusions.
    Tetikkurt C; Yılmaz N; Tetikkurt S; Gundogdu Ş; Disci R
    Monaldi Arch Chest Dis; 2018 Sep; 88(3):944. PubMed ID: 30203633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Application of international system for reporting serous fluid cytology (ISRSFC) in effusion samples-a prospective study in an oncology setting.
    Sachan R; Gupta A; Awasthi PN; Singh P; Anand N; Chandra S; Gaur G; Husain N; Sachan KD
    J Am Soc Cytopathol; 2023; 12(5):351-361. PubMed ID: 37244848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
    Cozzi I; Oprescu FA; Rullo E; Ascoli V
    Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A retrospective analysis of pleural effusion specimens based on the newly proposed International System for Reporting Serous Fluid Cytopathology.
    Xu Y; Hu AY; Wang SM; Wang Q; Pan YC; Zhang SH
    Diagn Cytopathol; 2021 Sep; 49(9):997-1007. PubMed ID: 34019334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens.
    Saab J; Hoda RS; Narula N; Hoda SA; Geraghty BE; Nasar A; Alperstein SA; Port JL; Giorgadze T
    Cancer Cytopathol; 2017 Feb; 125(2):128-137. PubMed ID: 28207201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.